Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galecto, Inc. (GLTO : NSDQ)

• Company Description    Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $1.39 Daily Weekly Monthly 20 Day Moving Average: 60,983 shares Shares Outstanding: 25.26 (millions) Market Capitalization: $35.11 (millions) Beta: 1.22 52 Week High: $7.80 52 Week Low: $1.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -35.94% -29.81% 12 Week -26.06% -19.78% Year To Date -54.13% -45.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 STATE STREET SUITE 100 - BOSTON,MA 02109 DNK ph: 45-7070-5210 fax: - None http://www.galecto.com

• General Corporate Information    Officers Hans T. Schambye - President; Chief Executive Officer and Director Carl Goldfischer - Chairman Jonathan Freve - Chief Financial Officer Jayson Dallas - Director Chau Q. Khuong - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36322Q107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 25.26 Most Recent Split Date: (:1) Beta: 1.22 Market Capitalization: $35.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -26.42% vs. Previous Quarter: -26.42% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -45.22 12/31/21 - -38.28 09/30/21 - -33.90 ROA 03/31/22 - -43.08 12/31/21 - -36.73 09/30/21 - -32.58 Current Ratio 03/31/22 - 13.45 12/31/21 - 24.23 09/30/21 - 18.63 Quick Ratio 03/31/22 - 13.45 12/31/21 - 24.23 09/30/21 - 18.63 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 4.01 12/31/21 - 4.64 09/30/21 - 5.13 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©